Guidance, NICE advice and quality standards in development | Guidance

Showing 341 to 350 of 388

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6413]	Technology appraisal guidance	15 July 2026
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]	Technology appraisal guidance	TBC
Tarlatamab for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]	Technology appraisal guidance	13 January 2027
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women [ID1401]	Technology appraisal guidance	TBC
Technologies for the rapid diagnosis of endometriosis	Health technology evaluation	8 October 2026
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]	Technology appraisal guidance	TBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]	Technology appraisal guidance	8 April 2026
Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]	Technology appraisal guidance	TBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]	Technology appraisal guidance	9 September 2026
Third molars (impacted) - prophylactic removal [ID898]	Technology appraisal guidance	TBC